Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 2;7:33. doi: 10.1038/s41392-021-00855-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — Clinical significance of EPHA2 and PDGFRA in GBM. a Representative immunohistochemistry images of EPHA2 and PDGFRA proteins on continuous tissue sections. Scale Bar = 200 μm (upper) and 50 μm (lower). b Kaplan–Meier survival analysis on cases with PDGFRA^High/EPHA2^High vs. PDGFRA^High/EPHA2^Low from our glioma cohort. c Survival curve comparison between cases with PDGFRA^High/EPHA2^High and different molecular subtypes according to TCGA_GBM mRNA expression dataset. d Survival curve comparison between cases with PDGFRA^High/EPHA2^Low and different molecular subtypes according to TCGA_GBM mRNA expression dataset. e Kaplan–Meier survival analysis on cases with PDGFRA^High/EPHA2^High vs. all other cases from our glioma cohort. f Case count with different protein expression patterns from our glioma cohort according to tumor grades. g, h Kaplan–Meier survival analysis of different treatment ways under specific gene expression patterns according to TCGA_GBM database. i Therapeutic effects of treatment ways on survival time of patients with specific gene expression patterns.